CABA Cabaletta Bio
- 12.880
- +0.530+4.29%
Cabaletta Bio News
Cabaletta Bio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $30 Price Target
William Blair Reaffirms Their Buy Rating on Cabaletta Bio (CABA)
Buy Rating Affirmed for Cabaletta Bio as CABA-201 Enters RESET Trial With Promising Therapeutic Potential
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target
Cabaletta Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Cabaletta Bio (CABA)
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target
Cabaletta Bio Analyst Ratings
Wells Fargo Releases a Buy Rating on Cabaletta Bio (CABA)
Cabaletta Bio Earns 'Buy' Rating on Impressive Clinical Progress and Strategic Market Positioning
Cabaletta Bio (CABA) Gets a Buy From TD Cowen
Cabaletta Bio Analyst Ratings
Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally
Morgan Stanley Cuts Price Target on Cabaletta Bio to $25 From $28 as FDA Probes T-Cell Malignancies in CAR-T Cell Therapy, Keeps Overweight Rating
Analysts Offer Insights on Healthcare Companies: Edesa Biotech (EDSA), Cabaletta Bio (CABA) and Rallybio (RLYB)
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target
Cabaletta Bio Analyst Ratings
Watching Cabaletta Bio; Hearing Traders Circulate Cantor Fitzgerald Saying "We're Not Going To Be Spooked By This Amorphous 'FDA Is Looking Into This' Headline. We Have Accepted All Sorts Of Development Risks" Defends Buy Rating With $50 Price Target
Analysis
Price Target
No Data
